Helix BioPharma Corp. is experiencing a notable surge in its stock price, gaining over 4% in today's trading session.
Helix BioPharma Corp. (HBP.TO) is rising today, with shares up by 4.35% to CA$0.96. This movement reflects a positive sentiment among investors as the company navigates the complexities of the biotech landscape.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$73.32M
52W high
$2.75
52W low
$0.85
1W change
+4.35%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 160.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+160.4% Upside
Current Price
C$0.96
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
111.3%
Annualized
90-Day Vol
77.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.90 | C$0.62 – C$1.33 |
| 60 trading days | C$0.85 | C$0.50 – C$1.47 |
| 90 trading days | C$0.80 | C$0.41 – C$1.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Helix BioPharma's strategic developments, especially in their therapeutic programs, as these could significantly influence future stock performance.
Helix BioPharma Corp. Market Cap Reaches CA$73.32 Million
With a market cap of CA$73.32 million, Helix BioPharma remains a small player in the biotech sector, making it susceptible to volatility.
Bull case
Today's stock rise may stem from investor optimism about Helix BioPharma's efforts to develop innovative therapies, particularly L-DOS47 for lung cancer. If successful, this could lead to substantial returns.
Bear case
Despite today's gains, Helix BioPharma faces challenges, including a history of financial losses and a tough capital markets environment that could hinder future growth.
Market Performance Overview
Advertisement
Helix BioPharma Corp. is rising today, with a notable increase of 4.35% in its stock price. This uptick comes amid broader interest in biotech stocks, as investors look for opportunities in innovative therapies. The company's current market cap stands at CA$73.32 million, indicating its position as a small-cap player within the industry.
Strategic Developments
While there haven't been recent announcements from Helix BioPharma, the ongoing focus on developing L-DOS47 as a treatment for Non-Small Cell Lung Carcinoma remains a key driver of investor interest. Success in this area could lead to significant advancements for the company and its shareholders.
Investor Considerations
Investors should approach Helix BioPharma with caution, given its history of financial losses and the challenges faced by small-cap biotech firms. However, today's rise in stock price may signal a shift in sentiment, making it essential to stay informed about the company's developments and market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
